Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )

Centre Hospitalier Régional Metz-Thionville5 enrolled

Overview

Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (\>200 nmol/L) who had a history of cardiovascular disease and notable thromboembolic events.

The biological and clinical outcomes related to Lipoprotein-apheresis DFPP treatment and the associated cardiovascular and thromboembolic events will be described in these patients. Additionally, the impact of DFPP on biological and clinical markers including LDL cholesterol, triglycerides, fibrinogen, hemoglobin, platelet count, C-reactive protein (CRP), blood pressure, plasma volume treated, volume of albumin substitution, volume of plasma rejected, and duration of each Lipoprotein-apheresis DFPP session will be evaluated .

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lipoprotein(a)Lipoprotein-apheresis Double-filtration Plasmapheresis Hemodialysis Complication End Stage Chronic Renal Failure

Medical Language ↔ Plain English

Inclusion Criteria: * Chronic hemodialysis patients with elevated Lp(a) levels (\>200 nmol/L) and a history of cardiovascular disease and/or thromboembolic events who underwent DFPP sessions as part of their management Exclusion Criteria: * -Patients with progressive, active disease, presenting with severe general deterioration and a limited life expectancy * Patients presenting with hemodynamic instability * Patients presenting with acute kidney diseases.